Skip to main content
Berry Genomics Co.,Ltd logo

Berry Genomics Co.,Ltd — Investor Relations & Filings

Ticker · 000710 ISIN · CNE000000PN7 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,009 across all filing types
Latest filing 2020-04-14 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 000710

About Berry Genomics Co.,Ltd

https://www.berrygenomics.com

Berry Genomics Co.,Ltd. is a biotechnology enterprise specializing in clinical genomics and genetic testing services. The company focuses on the research, development, and commercialization of genomic technologies for clinical applications. Its core portfolio includes non-invasive prenatal testing (NIPT), utilizing high-throughput sequencing to screen for chromosomal abnormalities. Beyond reproductive health, the company provides genomic solutions for oncology diagnostics, including early cancer screening and companion diagnostics, as well as testing for hereditary diseases. Berry Genomics leverages advanced sequencing platforms and proprietary bioinformatics pipelines to deliver precision medicine tools to healthcare providers and research institutions. The company is recognized for its role in the clinical application of Next-Generation Sequencing (NGS) and its extensive genomic databases used to enhance diagnostic accuracy and therapeutic outcomes.

Recent filings

Filing Released Lang Actions
非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanatory report on non-operating fund occupation and other related party fund transactions for the year 2019 by Chengdu Berry Genomics Co., Ltd. It includes references to an audit report issued on April 14, 2020, and contains detailed financial data related to non-operating funds and related party transactions. The document is prepared by a certified public accounting firm and is intended for submission to the China Securities Regulatory Commission and related institutions. It is not a full annual report but a standalone audit-related report focusing on specific financial aspects (non-operating fund occupation and related party transactions). This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report with detailed financial data and explanations, not a full annual report or a simple announcement. The document length is 4435 characters, which is sufficient to contain substantive financial data and analysis, not just a brief announcement or certification.
2020-04-14 Chinese
北京贝瑞和康生物技术有限公司审计报告
Annual Report Classification · 95% confidence The document contains detailed financial statements including balance sheet items such as current assets, liabilities, equity, and income statement items like revenue, costs, expenses, and other comprehensive income. The presence of comparative figures for current and prior periods, detailed notes references, and comprehensive financial data indicates this is a full financial report. The length of the document (15,000 characters) and the depth of financial detail suggest it is not a brief announcement or a certification but a substantive financial report. The content aligns with an Annual Report (10-K) which covers full financial performance and company activity for a fiscal year. There is no indication that this is merely an announcement or a partial report like an interim or quarterly report. Therefore, the document is best classified as an Annual Report (10-K).
2020-04-14 Chinese
独立董事关于公司控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Audit Report / Information Classification · 95% confidence The document is an independent directors' special statement and opinion regarding the company's controlling shareholders and related parties occupying company funds and the company's external guarantees. It references regulatory notices from the China Securities Regulatory Commission and Shenzhen Stock Exchange listing rules. The content focuses on compliance and assurance about related party transactions and guarantees, without presenting financial statements or detailed audit results. The document length is short (762 characters), and it is a formal statement by independent directors rather than a full audit report or annual report. Therefore, it fits best under Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and results of internal or regulatory stress tests, excluding full annual reports. FY 2023
2020-04-14 Chinese
独立董事关于2019年度内部控制自我评价报告的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's 2019 internal control self-evaluation report. It references regulatory frameworks related to internal control and governance but does not contain the full internal control report itself. The document length is short (675 characters), and it appears to be a certification or attestation by independent directors rather than the full report. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS) rather than the report itself.
2020-04-14 Chinese
2019年度总经理工作报告
Management Reports Classification · 95% confidence The document is titled as the "2019年度总经理工作报告" which translates to "2019 Annual General Manager Work Report." It contains detailed financial data for the year 2019, including revenue, profit, R&D expenses, and operational highlights. The report discusses the company's overall business performance, financial indicators, development strategy, and future outlook. It is a comprehensive management report covering the full fiscal year 2019, with substantive financial data and analysis. This matches the definition of a Management Report (MDA), which provides management's detailed explanation of financial results, business trends, and outlook. The document is not a full Annual Report (10-K) as it lacks the full financial statements and audit opinions, nor is it a simple earnings release or presentation. Therefore, the best classification is Management Reports (MDA).
2020-04-14 Chinese
2019年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the 2019年度财务决算报告 (2019 Annual Financial Settlement Report) of 成都市贝瑞和康基因技术股份有限公司. It contains detailed financial data for the year 2019, including income statement, balance sheet, cash flow statement, and financial ratios. It also mentions that the financial statements have been audited with an unqualified opinion by an accounting firm. The document is comprehensive and covers the full fiscal year financial performance, which aligns with the definition of an Annual Report (10-K). The length of the document (4720 characters) and the detailed financial data confirm it is the report itself, not just an announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2019
2020-04-14 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.